MedPath

Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A

Overview

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions

  • CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection
  • Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Research Report

Published: Jul 23, 2025

Maraviroc (DB04835): A Comprehensive Monograph on a First-in-Class CCR5 Antagonist from HIV-1 Therapy to Broad-Spectrum Immunomodulation

1.0 Executive Summary

Maraviroc (DrugBank ID: DB04835) represents a significant milestone in the history of antiretroviral therapy (ART). As the first orally bioavailable small molecule antagonist of the C-C chemokine receptor type 5 (CCR5), its approval marked the introduction of a new class of HIV medications in over a decade.[1] Developed by Pfizer and marketed under the brand names Selzentry and Celsentri, Maraviroc introduced a novel mechanism of action that fundamentally differs from preceding antiretroviral agents. Instead of inhibiting viral enzymes once HIV has already infected a host cell, Maraviroc functions as an entry inhibitor, blocking the virus at the cell surface before infection can occur.[3]

The drug's primary clinical indication is for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, but its use is highly specific. It is effective only against viral strains that utilize the CCR5 co-receptor for cellular entry, known as CCR5-tropic (or R5) virus.[1] This mechanistic specificity necessitates pre-treatment viral tropism testing, positioning Maraviroc as an early example of personalized medicine in infectious disease management.[6] Its clinical utility is most established in treatment-experienced patients with multidrug-resistant HIV, for whom it provides a new therapeutic option with no cross-resistance to other drug classes.[2]

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/23
Not Applicable
Recruiting
Emmanuel Carrera
2025/05/15
Phase 2
Not yet recruiting
HealthBio, Inc.
2025/02/28
Phase 2
Not yet recruiting
2025/02/03
Not Applicable
Not yet recruiting
Federal University of São Paulo
2024/07/19
Phase 2
Recruiting
2023/07/06
Phase 2
Completed
2022/07/22
Phase 1
Recruiting
2021/07/19
Phase 2
UNKNOWN
2021/07/16
Phase 4
Completed
2021/03/09
Phase 2
Recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
ViiV Healthcare Company
49702-223
ORAL
150 mg in 1 1
9/26/2022
ViiV Healthcare Company
49702-233
ORAL
25 mg in 1 1
9/26/2022
XLCare Pharmaceuticals Inc.
72865-231
ORAL
150 mg in 1 1
7/12/2023
i3 Pharmaceuticals, LLC
72319-025
ORAL
300 mg in 1 1
8/18/2023
Navinta LLC
68475-007
ORAL
300 mg in 1 1
6/23/2025
Camber Pharmaceuticals, Inc.
31722-579
ORAL
150 mg in 1 1
1/27/2022
ViiV Healthcare Company
49702-235
ORAL
75 mg in 1 1
9/26/2022
Navinta LLC
68475-008
ORAL
150 mg in 1 1
6/23/2025
Physicians Total Care, Inc.
54868-5809
ORAL
300 mg in 1 1
5/23/2012
XLCare Pharmaceuticals Inc.
72865-232
ORAL
300 mg in 1 1
7/12/2023

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
Celsentri Film-Coated Tablet 150mg
SIN13640P
TABLET, FILM COATED
150mg
4/30/2009

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
CELSENTRI TAB 300MG
N/A
N/A
N/A
7/17/2008
CELSENTRI TAB 150MG
N/A
N/A
N/A
7/17/2008

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
CELSENTRI
viiv healthcare ulc
02299844
Tablet - Oral
150 MG
9/26/2007
CELSENTRI
viiv healthcare ulc
02299852
Tablet - Oral
300 MG
9/26/2007

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
CELSENTRI 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
07418003
COMPRIMIDO RECUBIERTO CON PELÍCULA
Uso Hospitalario
Commercialized
CELSENTRI 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
07418008
COMPRIMIDO RECUBIERTO CON PELÍCULA
Diagnóstico Hospitalario
Commercialized
MARAVIROC TARBIS 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Tarbis Farma S.L.
89504
COMPRIMIDO RECUBIERTO CON PELÍCULA
Diagnóstico Hospitalario
Commercialized
MARAVIROC TARBIS 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Tarbis Farma S.L.
89505
COMPRIMIDO RECUBIERTO CON PELÍCULA
Diagnóstico Hospitalario
Commercialized
MARAVIROC WAYMADE 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Waymade B.V.
89845
COMPRIMIDO RECUBIERTO CON PELÍCULA
Diagnóstico Hospitalario
Not Commercialized
MARAVIROC WAYMADE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
Waymade B.V.
89844
COMPRIMIDO RECUBIERTO CON PELÍCULA
Diagnóstico Hospitalario
Not Commercialized

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.